Login to Your Account

CMS biosimilar payment plan nearly flunks House test

By Mari Serebrov
Regulatory Editor

Thursday, February 4, 2016

Delays in putting out much-needed guidance earned the FDA a C+ Thursday in its implementation of the biosimilar path, but the Centers for Medicare & Medicaid Services (CMS) got a D- for not even trying.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription